Insider filing · ALNY
Jeffrey V. Poulton
EVP, Chief Financial Officer
profile →
Alnylam Pharmaceuticals, Inc.
ALNY · Healthcare · 56 filings in 24 months
ticker →
Jeffrey V. Poulton sold $823K of Alnylam Pharmaceuticals (ALNY)
Executed Aug 18 2025, disclosed Aug 19 2025, 1 day later.
Value, as filed
$823K
1,814 sh across 3 lots
Executed
Aug 18 2025
the trade date, as filed
Disclosed
Aug 19 2025
1 day after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
JPJeffrey V. Poulton (EVP, Chief Financial Officer) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Alnylam Pharmaceuticals, Inc. (ALNY). The largest single filing was $1.5M of ALNY (3,308 sh across 7 lots, as filed), executed Oct 2 2025.
The name
ALNYHealthcare · Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Jeffrey V. Poulton in ALNY
ALNYSALE
Alnylam Pharmaceuticals, Inc.
$386K1,192 sh across 2 lots
Exec Mar 4
Filed Mar 6 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. $441K
1,351 sh across 3 lots
Exec Mar 2
Filed Mar 4 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. $695K
2,242 sh × $310.08
Exec Feb 13
Filed Feb 17 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. $384K
1,054 sh across 3 lots
Exec Jan 12
Filed Jan 14 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. $1.5M
3,308 sh across 7 lots
Exec Oct 2 2025
Filed Oct 3 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. $238K
945 sh × $251.42
Exec Nov 26 2024
Filed Nov 27 2024 · 5:30 PM ET